CFO Gregory Martini (KYTX) listed as insider in Kyverna Form 3

Rhea-AI Filing Summary

Kyverna Therapeutics, Inc. filed a Form 3 identifying Gregory S. Martini as a reporting person in his role as Chief Financial Officer. The filing does not list any share purchases, sales, acquisitions, dispositions, or derivative exercises, and shows no reported holdings or derivative positions.

Key Terms

Form 3, Chief Financial Officer, ten_percent_owner, insider filing

4 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3):"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Chief Financial Officer financial

""officer_title": "Chief Financial Officer""

A Chief Financial Officer (CFO) is the person in charge of a company's money and financial planning. They decide how to spend, save, and invest funds to help the company grow and stay stable. Their role is important because good financial decisions keep the company healthy and successful.

ten_percent_owner financial

""is_ten_percent_owner": 0"

insider filing regulatory

"INSIDER FILING DATA (Form 3):"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Martini Gregory S.

(Last) (First) (Middle)

C/O KYVERNA THERAPEUTICS, INC.

5980 HORTON ST., STE 200

(Street)

EMERYVILLE CALIFORNIA 94608

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
05/18/2026

3. Issuer Name and Ticker or Trading Symbol
Kyverna Therapeutics, Inc. [ KYTX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Samantha H. Eldredge, as Attorney-in-Fact	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Kyverna Therapeutics (KYTX) disclose about Gregory S. Martini in this Form 3?

The Form 3 identifies Gregory S. Martini as a reporting person and Chief Financial Officer of Kyverna Therapeutics, Inc. It establishes his status as an officer but does not show any reported security holdings or derivative positions in this data.

Does the Kyverna (KYTX) Form 3 show any insider share purchases or sales by Gregory S. Martini?

No insider share purchases or sales are shown for Gregory S. Martini in this Form 3 data. The transaction summary lists zero buys, zero sells, and no derivative exercises, indicating no reportable trading activity in this filing excerpt.

Are there any derivative securities reported for Gregory S. Martini in the Kyverna (KYTX) Form 3?

No derivative securities are reported for Gregory S. Martini in this Form 3. The derivative summary is empty and the transaction summary lists zero derivative transactions or exercises, indicating no options, warrants, or similar instruments in this dataset.

What roles or ownership thresholds are indicated for Gregory S. Martini at Kyverna (KYTX)?

Gregory S. Martini is indicated as an officer serving as Chief Financial Officer, and he is not listed as a ten percent owner. The data marks him as an officer only, without director status or large ownership designation.

Do the Form 3 footnotes for Kyverna (KYTX) and Gregory S. Martini add ownership details?

The Form 3 footnotes section in this dataset contains only a null entry, so it adds no extra information. There are no footnote clarifications about voting power, indirect holdings, or trading plans for Gregory S. Martini here.